Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Disease
87%
Neoplasm
68%
Diffuse Large B-Cell Lymphoma
66%
Overall Survival
64%
Malignant Neoplasm
50%
Transplantation
49%
Hodgkin's Lymphoma
47%
Peripheral T-Cell Lymphoma
41%
Mantle Cell Lymphoma
38%
Hematopoietic Stem Cell
37%
Acute Myeloid Leukemia
36%
Cell Transplantation
32%
Multiple Myeloma
32%
Drug Megadose
31%
B Cell
31%
T Cell
30%
Follicular Lymphoma
29%
Rituximab
28%
B-Cell Chronic Lymphocytic Leukemia
24%
Oncology
24%
Clinical Trial
24%
Bone Marrow Transplantation
23%
Progression Free Survival
23%
Breast Cancer
23%
Autologous Stem Cell Transplantation
21%
Large-Cell Lymphoma
21%
Metastatic Carcinoma
20%
B-Cell Lymphoma
19%
Cancer
18%
Tumor Cell
18%
Hematopoietic Stem Cell Transplantation
18%
Radiation Therapy
17%
Autotransplantation
17%
Stem Cell
17%
High Dose Chemotherapy
16%
Lenalidomide
16%
Autologous Hematopoietic Stem Cell Transplantation
15%
Autologous Bone Marrow Transplantation
15%
Prognostic Factor
15%
Doxorubicin
15%
Diagnosis
14%
Cyclophosphamide
14%
T-Cell Lymphoma
13%
Lymphocytic Lymphoma
12%
Minimal Residual Disease
12%
Hematologic Malignancy
12%
Tumor Progression
12%
Multivariate Analysis
12%
Lymphoma
12%
International Prognostic Index
12%
Leukemia
11%
Vincristine
11%
NK T Cell Lymphoma
11%
Allogeneic Hematopoietic Stem Cell Transplantation
11%
Risk Stratification
11%
Cancer Cell
11%
Gene Expression
11%
Prednisone
11%
Symptom
11%
Central Nervous System
11%
Gene Expression Profiling
11%
Germinal Center
10%
Infection
10%
Stem Cell Transplant
10%
Hazard Ratio
10%
Acute Lymphoblastic Leukemia
10%
Myelodysplastic Syndrome
10%
Ganglioneuroblastoma
10%
Burkitt's Lymphoma
9%
Myeloma
9%
In Vitro
9%
Classical Hodgkin Lymphoma
9%
Anaplastic Large Cell Lymphoma
9%
Pancreas Cancer
9%
Lymphoma Cell
9%
Allogeneic Stem Cell Transplantation
8%
Morphology
8%
Adverse Event
8%
Survival Rate
8%
Event Free Survival
8%
Peripheral Stem Cell Transplantation
8%
Failure Free Survival
8%
Biopsy
8%
Breast Tumor
8%
Biological Marker
8%
Targeted Therapy
8%
Nodular Melanoma
7%
Hematopoietic Stem Cell
7%
Patient with Non-Hodgkins Lymphoma
7%
Disease Free Survival
7%
Cancer Therapy
7%
Human Immunodeficiency Virus
7%
Maintenance Therapy
7%
Graft Versus Host Reaction
7%
Interleukin 8 Receptor, Beta
7%
Aggressive Lymphoma
7%
Cancer Growth
7%
Apheresis
7%
Clinical Feature
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
75%
Neoplasm
60%
Nonhodgkin Lymphoma
56%
Chemotherapy
52%
Disease
51%
Overall Survival
37%
Mouse
36%
Small Interfering RNA
25%
Diffuse Large B Cell Lymphoma
24%
Multiple Myeloma
24%
Clinical Trial
21%
Hodgkin Disease
20%
Pancreas Cancer
20%
Breast Cancer
20%
Acute Myeloid Leukemia
19%
Doxorubicin
19%
Mantle Cell Lymphoma
19%
Rituximab
18%
Lenalidomide
18%
Remission
18%
Progression Free Survival
17%
Tumor Growth
15%
Peripheral T Cell Lymphoma
15%
Cyclophosphamide
14%
High Dose Chemotherapy
14%
Prostate Cancer
13%
Protein P53
13%
Chronic Lymphatic Leukemia
12%
Follicular Lymphoma
12%
Farnesyl Trans Transferase
12%
Prednisone
11%
Nanoparticle
11%
Metastasis
11%
Hematologic Malignancy
10%
Breast Tumor
10%
B Cell Lymphoma
10%
Vincristine
10%
Large Cell Lymphoma
9%
Adverse Event
9%
Cancer Growth
9%
Bisphosphonic Acid Derivative
9%
Melanoma
8%
Isoprenoid
8%
Combination Therapy
8%
Biological Marker
8%
Leukemia
8%
Anticarcinogen
8%
Polycation
8%
Survival Rate
7%
Tumor Microenvironment
7%
Myelodysplastic Syndrome
7%
Immunotherapy
7%
Dexamethasone
7%
Mouse Model
7%
Lymphoma
6%
Cytokine
6%
Cytotoxicity
6%
Chemokine
6%
NK T Cell Lymphoma
6%
Iodine-131
6%
Myeloma
6%
Chimeric Antigen Receptor
6%
Etoposide
6%
T Cell Lymphoma
6%
Medulloblastoma
6%
Solid Malignant Neoplasm
6%
Iodine-125
6%
Thrombocytopenia
6%
Polyamine
5%
Event Free Survival
5%
Nucleic Acid
5%
Heparin Induced Thrombocytopenia
5%
microRNA
5%
Neuroblastoma
5%
Triazole
5%
Infection
5%
Antiapoptotic
5%
Bortezomib
5%
Graft Versus Host Reaction
5%
Pancreas Adenocarcinoma
5%
Therapy Resistance
5%
Granulocyte Colony Stimulating Factor
5%
Porphyrin
5%
Plerixafor
5%
Phase I Trials
5%
Injury
5%
Pharmacokinetics
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Epileptic Absence
5%
Failure Free Survival
5%
Tumor Suppressor Protein
5%
Urogastrone
5%
Venous Thromboembolism
5%
Polyethylene Glycol
5%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
43%
Non-Hodgkin Lymphoma
43%
Lymphoma
33%
Diffuse Large B-cell Lymphoma (DLBCL)
31%
Overall Survival
23%
Peripheral T-cell Lymphoma
22%
Chemotherapy
22%
Acute Myeloid Leukemia
19%
Multiple Myeloma
16%
Relapsed or Refractory
16%
Mantle Cell Lymphoma
15%
Hodgkin Disease
15%
Bone Marrow Transplantation
14%
Allogeneic Bone Marrow Transplantation
14%
NCCN Guidelines
14%
Follicular Lymphoma
13%
Marrow Transplantation
13%
High-dose Chemotherapy
13%
High-dose Therapy
12%
T Cells
12%
Tumor
12%
Transplantation
12%
Bone Marrow
12%
Progression-free Survival
10%
Hodgkin Lymphoma
10%
Clinical Trials
9%
Confidence Interval
9%
Complete Remission
9%
Autologous Transplantation
9%
Oncology
9%
In Cancer
8%
Rituximab
8%
Hematopoietic Stem Cell Transplantation
8%
Chronic Lymphocytic Leukemia
8%
Lenalidomide
8%
Graft-versus-host Disease (GvHD)
8%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Initial Treatment
7%
Hematological Malignancies
7%
T-cell Lymphoma
7%
Nebraska
7%
Large B-cell Lymphoma
7%
Hematopoietic Cell Transplantation
7%
Leukemia
6%
Older Adults
6%
Older Patients
6%
Newly Diagnosed
6%
United States
6%
Relapsed Lymphoma
6%
Myeloma
6%
B-cell Lymphoma
6%
Tumor Cells
5%
Malignancy
5%
Radiation Therapy
5%
Myelodysplastic Syndrome
5%
Cyclophosphamide
5%
Doxorubicin
5%
Small Interfering RNA (siRNA)
5%
Tumor Microenvironment
5%
5-year Survival
5%
Peripheral Stem Cells
5%
Apoptosis
5%
B-cell Lymphoma 2 (Bcl-2)
5%
High Risk
5%